Literature DB >> 18382189

Can we prevent acute kidney injury?

Ramesh Venkataraman1.   

Abstract

OBJECTIVE: To review the literature on prevention of acute kidney injury (AKI). DATA SOURCE: MEDLINE- and PubMed-based review of literature published from 1965 to 2007.
CONCLUSIONS: AKI is very common among critically ill patients. Even mild forms of AKI have significant attributable mortality. Hence, it is imperative that every effort to prevent AKI be made in clinical practice. However, there are very few interventions that have been shown to consistently prevent AKI. Measures such as adequate hydration, maintenance of adequate circulating blood volume and mean arterial pressure, and avoidance of nephrotoxins are still the mainstay of prevention. Loop diuretics and "renal-dose" dopamine have been clearly shown not to prevent AKI and may, in fact, do harm. Among the remaining pharmacologic options, N-acetylcysteine has the strongest evidence in prevention of AKI. Fenoldopam and theophylline need further investigation before being used to prevent septic AKI and contrast nephropathy, respectively. The role of prophylactic dialysis in preventing contrast nephropathy needs to be investigated further.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18382189     DOI: 10.1097/CCM.0b013e318168c74a

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  14 in total

Review 1.  In search of mechanisms associated with mesenchymal stem cell-based therapies for acute kidney injury.

Authors:  Danilo C de Almeida; Cassiano Donizetti-Oliveira; Priscilla Barbosa-Costa; Clarice St Origassa; Niels Os Câmara
Journal:  Clin Biochem Rev       Date:  2013-11

2.  N-acetylcysteine is effective for prevention but not for treatment of folic acid-induced acute kidney injury in mice.

Authors:  Hong-Zhi Wang; Zhi-Yong Peng; Xiao-Yan Wen; Thomas Rimmelé; Jeffery V Bishop; John A Kellum
Journal:  Crit Care Med       Date:  2011-11       Impact factor: 7.598

Review 3.  Protection of nitro-fatty acid against kidney diseases.

Authors:  Weidong Wang; Chunling Li; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-30

Review 4.  Novel aspects of pharmacological therapies for acute renal failure.

Authors:  Ulrich Kunzendorf; Michael Haase; Lars Rölver; Anja Haase-Fielitz
Journal:  Drugs       Date:  2010-06-18       Impact factor: 9.546

5.  Evaluation and management of acute kidney injury in the intensive care unit.

Authors:  Timothy M Saettele; Jason Mohr; Gary A Salzman
Journal:  Mo Med       Date:  2012 Sep-Oct

Review 6.  Renal replacement therapy: a practical update.

Authors:  George Alvarez; Carla Chrusch; Terry Hulme; Juan G Posadas-Calleja
Journal:  Can J Anaesth       Date:  2019-02-06       Impact factor: 5.063

7.  Identification of candidate serum biomarkers for severe septic shock-associated kidney injury via microarray.

Authors:  Rajit K Basu; Stephen W Standage; Natalie Z Cvijanovich; Geoffrey L Allen; Neal J Thomas; Robert J Freishtat; Nick Anas; Keith Meyer; Paul A Checchia; Richard Lin; Thomas P Shanley; Michael T Bigham; Derek S Wheeler; Prasad Devarajan; Stuart L Goldstein; Hector R Wong
Journal:  Crit Care       Date:  2011-11-18       Impact factor: 9.097

8.  Protection against renal ischemia-reperfusion injury in vivo by the mitochondria targeted antioxidant MitoQ.

Authors:  Anna J Dare; Eleanor A Bolton; Gavin J Pettigrew; J Andrew Bradley; Kourosh Saeb-Parsy; Michael P Murphy
Journal:  Redox Biol       Date:  2015-04-29       Impact factor: 11.799

Review 9.  Intravascular administration of mannitol for acute kidney injury prevention: a systematic review and meta-analysis.

Authors:  Bo Yang; Jing Xu; Fengying Xu; Zui Zou; Chaoyang Ye; Changlin Mei; Zhiguo Mao
Journal:  PLoS One       Date:  2014-01-14       Impact factor: 3.240

10.  Section 2: AKI Definition.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.